Skip to content
OpenCapital
Get started

CRISPR Therapeutics CRSP EBITDA

EBITDA at other companies

Beam Therapeutics logo
Beam TherapeuticsBEAM
-$101.61M+10.7%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$102.98M-38.6%
Celcuity logo
CelcuityCELC
-$50.46M-39.8%
Arrowhead Research logo
Arrowhead ResearchARWR
——
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
——
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
——

Other financials

Income statement

See full
Revenue$1.5M+68.6%
Operating income-$130.2M+12.2%
Net income-$122.9M+9.6%
EPS (diluted)-$1.28+19.0%

Balance sheet

See full
Cash & equivalents$423.3M+80.0%
Total debt$787.6M+259%
Total equity$1.8B-0.8%
Total assets$2.7B+25.8%

Cash flow

See full
Operating cash flow-$108.9M-102%
CapEx$504.0K+145%
Free cash flow-$109.4M-102%

Valuation

See full
Market cap$5.33B+56.4%

Profitability

See full
Operating margin-15,754.2%-17,253pp
Net margin-13,856.5%-15,058pp
FCF margin-9,777.6%-10,759pp

Returns & leverage

See full
Return on equity-31.2%+43.7pp
Debt / equity0.4×+0.3×
Current ratio18×+2.3×

Where this comes from

Calculated from CRISPR Therapeutics’s reported figures.

−$130.2Mebit+
$4.3MDepreciation Depletion & Amortization
=-$125.93M

The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about CRISPR Therapeutics's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CRISPR Therapeutics's EBITDA?
CRISPR Therapeutics (CRSP) reported EBITDA of -$125.93M in Q1 2026.
How has CRISPR Therapeutics's EBITDA changed year-over-year?
CRISPR Therapeutics's EBITDA increased by 12.4% year-over-year, from -$143.69M to -$125.93M.
What is the long-term trend for CRISPR Therapeutics's EBITDA?
Over 2 years (2022 to 2025), CRISPR Therapeutics's EBITDA has grown at a -0.3% compound annual growth rate (CAGR), from -$648.99M to -$645.09M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.